Abstract
Development of a vaccine with enhanced efficacy compared to that of the Bacillus Calmette Guerin (BCG) vaccine is essential to reduce the global TB burden. This is challenging since an effective vaccine will need to induce protection that surpasses that induced by natural infection with M. tuberculosis and currently there are no identified biomarkers of protection. Nonetheless progress has been made over the last 20 years in the development and clinical evaluation of novel TB vaccines, evidenced by 15 candidate vaccines being tested in phase I clinical trials and 4 reaching phase IIb and III trials. In order to make further progress there is a need to further understanding of the interactions between M. tuberculosis and its host and for the development of ongoing partnerships to facilitate the design, harmonisation and funding of clinical trials.
Keywords: BCG, biomarker, correlates of protection, TB vaccine.
Current Respiratory Medicine Reviews
Title:Advances in TB Vaccinology
Volume: 9 Issue: 3
Author(s): Uta G. Hill and Clare R. Sander
Affiliation:
Keywords: BCG, biomarker, correlates of protection, TB vaccine.
Abstract: Development of a vaccine with enhanced efficacy compared to that of the Bacillus Calmette Guerin (BCG) vaccine is essential to reduce the global TB burden. This is challenging since an effective vaccine will need to induce protection that surpasses that induced by natural infection with M. tuberculosis and currently there are no identified biomarkers of protection. Nonetheless progress has been made over the last 20 years in the development and clinical evaluation of novel TB vaccines, evidenced by 15 candidate vaccines being tested in phase I clinical trials and 4 reaching phase IIb and III trials. In order to make further progress there is a need to further understanding of the interactions between M. tuberculosis and its host and for the development of ongoing partnerships to facilitate the design, harmonisation and funding of clinical trials.
Export Options
About this article
Cite this article as:
Hill G. Uta and Sander R. Clare, Advances in TB Vaccinology, Current Respiratory Medicine Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573398X113099990021
DOI https://dx.doi.org/10.2174/1573398X113099990021 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Shikimate Kinase (EC 2.7.1.71) from Mycobacterium tuberculosis: Kinetics and Structural Dynamics of a Potential Molecular Target for Drug Development
Current Medicinal Chemistry Challenges and Opportunities of Nanotechnological based Approach for the Treatment of Tuberculosis
Current Pharmaceutical Design A Study on the Biological Activity of 2-thioxo-imidazolidin-4-ones
Letters in Drug Design & Discovery Assessment and Management of Loose Bodies in the Knee Joint and Related Disease: A Narrative Review
Current Rheumatology Reviews Role of Alpha-1 Antitrypsin (AAT) in Ocular Allergy and Uveitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Mutation and Evolution of Antibiotic Resistance: Antibiotics as Promoters of Antibiotic Resistance?
Current Drug Targets Expression, Purification, Crystallization and Preliminary X-Ray Crystallographic Analysis of the Peptidoglycan Binding Region of the Ser/Thr Kinase PrkC from Staphylococcus aureus
Protein & Peptide Letters Translation Controlled mRNAs: New Drug Targets in Infectious Diseases?
Infectious Disorders - Drug Targets Initiation of the Immune Response by Extracellular Hsp72: Chaperokine Activity of Hsp72
Current Immunology Reviews (Discontinued) Clinical Applications of Choline PET/CT in Brain Tumors
Current Pharmaceutical Design Combination Antifungal Therapy for Invasive Aspergillosis: Utilizing New Targeting Strategies
Current Drug Targets - Infectious Disorders The Aromatic Stacking Interactions Between Proteins and their Macromolecular Ligands
Current Protein & Peptide Science Natural and Acquired Macrolide Resistance in Mycobacteria
Current Drug Targets - Infectious Disorders Ascaris lumbricoides: An Overview of Therapeutic Targets
Infectious Disorders - Drug Targets Genomic and Genetic Approaches for the Identification of Antifungal Drug Targets
Infectious Disorders - Drug Targets Editorial [Hot Topic: Tuberculosis (Part 1) (Guest Editor: Douglas B. Lowrie)]
Current Molecular Medicine Discovering and Developing New Medicines for Malaria Control and Elimination
Infectious Disorders - Drug Targets Disruption of Circadian Rhythms in Critical Illness - A Role of Hyperoxia-Induced Lung Injury
Current Pharmaceutical Design Modifier Gene Studies to Identify New Therapeutic Targets in Cystic Fibrosis
Current Pharmaceutical Design Indoleamine 2,3-dioxygenase, Tregs and Cancer
Current Medicinal Chemistry